- Short communication
Molecular cloning and characterization of a novel anti-TLR9 intrabody
Cellular & Molecular Biology Letters volume 18, pages 433–446 (2013)
Toll-like receptor 9 (TLR9) is a component of the innate immune system, which recognizes the DNA of both pathogens and hosts. Thus, it can drive autoimmune diseases. Intracellular antibodies expressed inside the ER block transitory protein functions by inhibiting the translocation of the protein from the ER to its subcellular destination. Here, we describe the construction and characterization of an anti-TLR9 ER intrabody (αT9ib). The respective single-chain Fv comprises the variable domains of the heavy and light chain of a monoclonal antibody (mAb; 5G5) towards human and murine TLR9. Co-expression of αT9ib and mouse TLR9 in HEK293 cells resulted in co-localization of both molecules with the ER marker calnexin. Co-immunoprecipitation of mouse TLR9 with αT9ib indicated that αT9ib interacts with its cognate antigen. The expression of αT9ib inhibited NF-κB-driven reporter gene activation upon CpG DNA challenge but not the activation of TLR3 or TLR4. Consequently, TLR9-driven TNFα production was inhibited in RAW264.7 macrophages upon transfection with the αT9ib expression plasmid. The αT9ib-encoding open reading frame was integrated into an adenoviral cosmid vector to produce the recombinant adenovirus (AdV)-αT9ib. Transduction with AdVαT9ib specifically inhibited TLR9-driven cellular TNFα release. These data strongly indicate that αT9ib is a very promising experimental tool to block TLR9 signaling.
Akira, S., Uematsu, S. and Takeuchi, O. Pathogen recognition and innate immunity. Cell 124 (2006) 783–801.
Kawai, T. and Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11 (2010) 373–384.
Lee, B.L., Moon, J.E., Shu, J.H., Yuan L., Newman, Z.R., Schekman, R. and Barton G.M. UNC93B1 mediates differential trafficking of endosomal TLRs. eLife. 00291.
Latz, E., Schoenemeyer, A., Visintin, A., Fitzgerald, K.A., Monks, B.G., Knetter, C.F., Lien, E., Nilsen, N.J., Espevik, T. and Golenbock, D.T. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat. Immunol. 5 (2004) 190–198.
Trivedi, S. and Greidinger, E.L. Endosomal Toll-like receptors in autoimmunity: mechanisms for clinical diversity. Therapy 6 (2009) 433–442.
Celhar, T., Magalhaes, R., and Fairhust, A.-M. TLR7 and TLR9 in SLE: when sensing self goes wrong. Immunol. Res. 53 (2012) 58–77.
Zeuner, R.A., Verthelyi, D., Gursel, M., Ishii, K.J. and Klinman, D.M. Influence of stimulatory and suppressive DNA motifs on host susceptibility to inflammatory arthritis. Arthritis Rheum. 48 (2003) 1701–1707.
O’Neill, L.A.J. Primer: Toll-like receptor signaling pathways-what do rheumatologists need to know? Nat. Clin. Pract. Rheumatol. 4 (2008) 319–327.
Daubeuf, B., Mathison, J., Spiller, S., Hugues, S., Herren, S., Ferlin, W., Kosco-Vilbois, M., Wagner, H., Kirschning, C.J., Ulevitch, R. and Elson, G. TLR4/MD-2 monoclonal antibody therapy affords protection in experimental models of septic shock. J. Immunol. 179 (2007) 6107–6114.
Meng, G., Rutz, M., Schiemann, M., Metzger, J., Grabiec, A., Schwandner, R., Luppa, P.B., Ebel, F., Busch, D.H., Bauer, S., Wagner, H. and Kirschning, C.J. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invest. 113 (2004) 1473–1481.
Vanags, D., Williams, B., Johnson, B., Hall, S., Nash, P., Taylor, A., Weiss, J. and Feeney, D. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomized trial. Lancet 368 (2006) 855–863.
Hennessy, E.J., Parker, A.E. and O’Neill, L.A.J. Targeting Toll-like receptors: emerging therapeutics? Nat. Rev. Drug. Discov. 9 (2010) 293–307.
Kuznik, A., Bencina, M., Svajger, U., Jeras, M. and Rozman, B. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J. Immunol. 186 (2011) 4794–4804.
Klinman, D.M., Zeuner, R., Yamada, H., Gursel, M., Currie, D. and Gursul, I. Regulation of CpG-induced immune activation by suppressive oligodeoxynucleotides. Ann. NY Acad. Sci. 1002 (2003) 112–123.
Barrat, F.J., Meeker, T., Chan, J.H., Guiducci, C. and Coffman, R.L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37 (2007) 3582–3586.
Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6 (2006) 823–835.
Graham, K.L., Lee, L.Y., Higgens, J.P., Steinmann, L., Utz, P.J. and Ho, P.P. Treatment with a toll-like receptor inhibitory CpG oligonucleotide delays and attenuates lupus nephritis in NZB/W mice. Autoimmunity 43 (2010) 140–155.
Böldicke, T. Blocking translocation of cell surface molecules from the ER to the cell surface by intracellular antibodies targeted to the ER. J. Cell Mol. Med. 11 (2007) 54–70.
Böldicke, T., Somplatzki, S., Sergeev, G. and Mueller, P.P. Functional inhibition of transitory proteins by intrabody-mediated retention in the endoplasmatic reticulum. Methods 56 (2012) 338–350.
Bilanges, B. and Stokoe, D. Direct comparison of the specificity of gene silencing using antisense oligonucleotides and RNAi. Biochem. J. 388 (2005) 573–583.
Qiu, S., Adema, C.M. and Lane, T. A computational study of off-target effects of RNA interference. Nucleic Acids Res. 33 (2005) 1834–1847.
Cao, T. and Heng, B.C. Intracellular antibodies (intrabodies) versus RNA interference for therapeutic applications. Ann. Clin. Lab. Sci. 35 (2005) 227–229.
Kirschning, C.J., Dreher, S., Maaß, B., Fichte, S., Schade, J., Köster, M., Noack, A., Lindenmaier, W., Wagner, H. and Böldicke, T. Generation of anti-TLR2 intrabody mediating inhibition of macrophage surface TLR2 expression and TLR2-driven cell activation. BMC Biotechnol. 10 (2010) 31.
Ahmad-Nejad, P., Häcker, H., Rutz, M., Bauer, S., Vabulas, R.M. and Wagner, H. Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 32 (2002) 1958–1968.
Böldicke, T., Weber, H., Mueller, P.P., Barleon, B. and Bernal, M. Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR). J. Immunol. Meth. 300 (2005) 146–159.
Böldicke, T., Tesar, M., Griesel, C., Rohde, M., Gröne, H.-J., Waltenberger J., Kollet, O., Lapidot, T., Yayon, A. and Weich, H. Single-chain antibodies recognizing the human vascular endothelial growth factor receptor-2 (VEGFR-2, flk-1) on the surface of primary endothelial cells and preselected CD34+ cells from cord blood. Stem Cells 19 (2001) 24–36.
Mayer, H., Bertram, H., Lindenmaier, W., Korff, T., Weber, H. and Weich, H. Vascular endothelial growth factor (VEGF-A) expression in human mesenchymal stem cells: autocrine and paracrine role on osteoblastic and endothelial differentiation. J. Cell Biochem. 95 (2005) 827–839.
Ospelt, C. and Gay, S. TLRs and chronic inflammation. Int. J. Biochem. Cell Biol. 42 (2010) 495–505.
Thomas, C.E., Ehrhardt, A. and Kay, M.A. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4 (2003) 346–358.
Swan, C.H., Bühler, B., Steinberger, P., Tschan, M.P., Barbas III, C.F. and Torbett, B.E. T-cell protection and enrichment through lentiviral CCR5 intrabody gene delivery. Gene Ther. 13 (2006) 1480–1492.
Cerullo, V., Seiler, M.P., Mane, V., Brunetti-Pierri, N., Clarke, C., Bertin, T.K., Rodgers, J.R. and Lee, B. Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol. Ther. 15 (2007) 378–385.
These authors contributed equally to this work.
About this article
Cite this article
Reimer, E., Somplatzki, S., Zegenhagen, D. et al. Molecular cloning and characterization of a novel anti-TLR9 intrabody. Cell Mol Biol Lett 18, 433–446 (2013). https://doi.org/10.2478/s11658-013-0098-8
- Recombinant antibodies
- Recombinant adenovirus
- Protein knockdown
- Intracellular toll-like receptors
- ER intrabodies
- Macrophage activation